Home > News > Optic Nerve Sheath Fenestration—Indications and Techniques
Neuro-ophthalmology, Retina/Vitreous
Read Time: 12 mins

Optic Nerve Sheath Fenestration—Indications and Techniques

Published Online: October 24th 2013 US Ophthalmic Review, 2013;6(2):125–131 DOI: http://doi.org/10.17925/USOR.2013.06.02.125
Authors: Nisha Mukherjee, Mays A El-Dairi, M Tariq Bhatti
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

The optic nerve is a white matter tract of the brain and its sheath is composed of pia mater, arachnoid mater, and dura mater. The subarachnoid space (SAS) of the optic nerve sheath, which contains cerebrospinal fluid, is contiguous with the SAS of the brain. Elevated intracranial pressure is transmitted to the optic nerve head through the SAS resulting in papilledema. Optic nerve sheath fenestration (ONSF) can be an effective surgical technique to preserve vision in patients with progressive optic neuropathy due to papilledema caused by idiopathic intracranial hypertension (IIH); however, a dreaded complication of ONSF is visual loss. This article will discuss the rationale, indications, and complications of ONSF. A variety of surgical techniques can be employed to perform an ONSF. In particular, the medial transconjuctival approach will be highlighted.

Keywords

Papilledema, optic nerve, idiopathic intracranial hypertension, optic nerve sheath fenestration

Article:

Optic nerve sheath fenestration (ONSF) is a surgical procedure used by ophthalmologists—particularly neuro-ophthalmologists and orbital specialists—to reduce the pressure within the subarachnoid space (SAS) of the optic nerve. The first notation of ONSF dates back to 1872 when it was described as a technique to relieve optic nerve head (ONH) edema, but at that time there was not a clear understanding of the pathogenesis of ONH edema.1

Subsequent landmark experiments by Hayreh validated the scientific use of ONSF in cases of ONH edema secondary to elevated intracranial pressure (ICP), also known as papilledema.2–8 Modern day studies have shown that ONSF can improve visual function in numerous conditions that produce ONH edema—especially in cases of visual loss secondary to papilledema caused by idiopathic intracranial hypertension (IIH). Unfortunately, much confusion arises from terminology used in the early literature that loosely applied the term papilledema to ONH edema due to a variety of pathologies. The appropriate use of papilledema is in the scenario of ONH edema due to elevated ICP. It is important to differentiate papilledema from ONH edema caused by local or systemic processes in the absence of elevated ICP (see Table 1).9,10 Additionally, the clinician should recognize pseudopapilledema, a condition that can mimic papilledema, is associated with elevation and an indistinct optic disc margin (see Figure 1).

This article’s purpose is to review the regional neuroanatomy of the optic nerve and the relationship of the SAS between the optic nerve and brain. In addition, we will discuss the rationale, indications, limitations, complications, and surgical techniques of ONSF. Finally, we will detail our preferred method for performing an ONSF.

Anatomy
Prior to undertaking a discussion of ONSF, we will outline the anatomy of the optic nerve, the optic nerve sheath, and the relationship of the SAS between the optic nerve and brain.

Optic Nerve
The optic nerve is anatomically divided into four distinct segments as it courses from the eye to the optic chiasm (see Figure 2). The optic nerve sheath refers to the three meningeal membranes—dura mater, arachnoid mater, and pia mater—that cover the optic nerve.

Optic Nerve Head
The first segment of the optic nerve is the ONH (or optic disc) located at the insertion of the nerve into the eye. The ONH represents the convergence of approximately 1.2 million axons of the retinal ganglion cells (RGCs). The ONH, which measures 1 mm in length and 1.5 mm in diameter, is represented by the physiologic blind spot on perimetry testing and is located approximately 4 mm nasal from the center of the macula (i.e. fovea). The ONH receives its blood supply from the circle of Zinn-Haller and the posterior ciliary arteries, which are branches of the ophthalmic artery.

Intraorbital Optic Nerve
The second segment of the optic nerve is the intraorbital optic nerve. At the ONH, the unmyelinated axons of the retinal nerve fiber layer (RNFL) make a 90° turn to exit the eye. The lamina cribrosa, a distinct region of the sclera consisting of stacks of fenestrated sheets of elastic fibers and connectivetissue, allows the passage of the optic nerve axons from the eye into the retrobulbar orbital space. After passing through the lamina cribrosa, the axons become covered by myelin derived from oligodendrocytes. The presence of myelin increases the diameter of the intraorbital optic nerve to approximately 3 mm. Posterior to and continuous with the sclera, the optic nerve procures a dural sheath, in addition to the arachnoid mater and pia mater. A unique anatomical feature of the intraorbital optic nerve is the fact that its length (28 mm) is nearly double the distance from the back of the eye to the orbital apex (15 mm). This configuration allows for the globe to freely rotate within the orbit and to compensate for any pathologic axial shifts within the orbit without causing visual dysfunction. The blood supply of the intraorbital optic nerve is derived from the pial network of vessels from the ophthalmic artery.9

Intracanalicular Optic Nerve
The intracanalicular optic nerve is the third segment of the optic nerve, and begins at the point where the optic nerve enters the optic canal. At the orbital apex, the dura mater covering the optic nerve fuses with the periorbita of the orbit. It is also at this location that the optic nerve isencircled by the annulus of Zinn represented by the tendinous insertions of the four recti muscles. The intracanalicular portion of the optic nerve is anchored within the optic canal, which measures approximately 8–10 mm in length and 5–7 mm in width. The intracanalicular optic nerve represents a watershed zone because it has a dual vascular supply, anteriorly from branches of the ophthalmic artery and posteriorly from small vessels arising from the internal carotid artery and the superior hyphophyseal artery.9

Intracranial Optic Nerve
The fourth and final segment of the optic nerve is the intracranial optic nerve. The optic nerve enters the cranial vault underneath the anterior clinoid process and over the ophthalmic artery. Upon exiting the optic canal, the dura of the optic nerve fuses with the periosteum of the middle cranial fossa. The nerve then travels a variable distance, ranging from 8–12 mm, before joining the optic chiasm. The intracranial optic nerve is supplied by branches from the internal carotid artery, the superior hypophyseal artery, anterior cerebral artery, and anterior communicating artery.9

Optic Nerve Sheath and Subarachnoid Space
The optic nerve is a misnomer because it is not a peripheral nerve but rather a central nervous system (CNS) white matter tract. As a result of this common lineage between the optic nerve and the CNS, the SAS of the optic nerve is contiguous with the SAS of the brain. As mentioned above, just posterior to the sclera, the optic nerve is surrounded by the leptomeninges. The arachnoid membrane of the optic nerve functions to support and protect the underlying axons. The arachnoid membrane of the optic nerve is continuous with the arachnoid membrane of the subdural intracranial space and allows for the free circulation of cerebrospinal fluid (CSF) around the optic nerve and brain.

By virtue of the fact that the optic nerve sheath serves as a CSF conduit between the brain and the eye, pathology involving the contents of the cranium can lead to pathology of the ONH. Particularly, CNS pathology characterized by increased ICP, including intracranial masses, infectious diseases, inflammatory diseases, and IIH, can impact the ONH, both structurally and functionally. When raised ICP is transmitted to the SAS within the optic nerve sheath, ONH edema ensues. Studies in Rhesus monkeys have shown that papilledema is the first ophthalmoscopic sign of raised ICP.2,4–8 Investigations examining the pathophysiology of papilledema have shown that axonal swelling at the ONH occurs due to a disturbance in theaxoplasmic transport system (see Figure 3).2,4–8,11 Nerve fiber dysfunction due to axonal swelling can result in loss of central vision, a decrease in peripheral vision, and, ultimately, optic atrophy.11

The exact relationship between the CSF dynamics of the brain SAS andoptic nerve SAS has not yet been fully elucidated. Historically, it has been generally accepted that there is free bi-directional communication between these two spaces. Recently, studies in patients with optic nerve pathology have shown chemical and radiographic evidence of compartmentation of the SAS of the optic nerve, suggesting that the optic neuropathy due to increased ICP may occur as a result of CSF collection at the ONH.12 Computed tomography-cisternography performed in patients with papilledema has shown reduced contrast-loaded CSF in the SAS of the optic nerve compared with the basal cistern, suggesting sequestration of CSF in the SAS of the optic nerve.13 It has also been shown that patients with papilledema have a higher concentration of lipocalin-like prostaglandin D synthase (L-PGDS) in the SAS of the optic nerve compared with the lumbar CSF, further supporting the CSF sequestration theory.13

Rationale for Optic Nerve Sheath Fenestration
ONSF is a surgical technique to reduce the hydrostatic pressure on the ONH. From a purely mechanical perspective it is believed that an opening within the optic nerve sheath will allow for a sudden and sustained drop in the SAS pressure and relief of the compartment syndrome on the ONH. However, the exact mechanism by which ONSF can relieve ONH edema is not entirely clear. It has been theorized that ONSF works by creating a CSF filter from the SAS of the optic nerve into the surrounding orbital tissue, thereby reducing the CSF volume and pressure surrounding the ONH. Magnetic resonance imaging conducted on patients in the early postoperative period after ONSF have demonstrated a fluid collection adjacent to the fenestration site that disappeared in the late postoperative period.14 Some patients who have undergone ONSF developed a cyst-like structure adjacent to the fenestration site, further implying a CSF filtration process.15 Additional support to the CSF filtration theory was achieved by creating a model using Bernoulli’s equation of fluid dynamics. According to Bernoulli’s equation, increased velocity of fluid leads to a decrease in pressure of that fluid. Based on this model, ONSF is thought to increase the velocity of CSF in the optic nerve sheath and thereby decrease the CSF pressure transmitted to ONH.16 The theory of CSF filtration induced by ONSF may help explain the clinical finding of decreased ONH edema in the fellow unoperated eye after unilateral ONSF despite persistent elevated ICP.16 An alternative theory for the relief of ONH edema based on histopathologic and radiologic findings suggests that ONSF promotes fibrous tissue proliferation at the incisional site, thereby preventing the transmission of elevated CSF pressure to the ONH.17,18

Indications for Optic Nerve Sheath Fenestration
ONSF has been tried in the setting of many optic neuropathies and has been found to improve visual function in some cases and worsen vision in others. To date, there has not been a randomized, prospective trial evaluating the efficacy of ONSF in papilledema. However, ONSF is most commonly indicated for optic neuropathy in the setting of raised ICP, particularly in the setting of medically resistant progressive visual loss due to IIH.

Optic Nerve Sheath Fenestration for Various Optic Neuropathies
The utility of ONSF in improving visual outcome of optic neuropathies from a variety of etiologies has been reported in small case series and case reports. In a case series of three patients with progressive visual loss due to radiation-induced optic neuropathy, ONSF improved visual function in all the patients.19 ONSF was found to be effective in patients with postdecompression blindness, a syndrome characterized by visualloss due to a ‘compartment syndrome’ in the intraorbital optic nerve after removal of a CNS lesion.20,21 Additionally, sporadic case reports have described improvement in visual function after ONSF in patients with osteopetrosis, optic nerve glioma, and chronic inflammatory demyelinating polyneuropathy.22–24

ONSF has also been utilized successfully in traumatic optic neuropathy. Guy et al. demonstrated reversal of progressive visual loss after ONSF in two patients with traumatic optic neuropathy. One of the patients had an optic nerve hematoma and the other developed delayed visual loss from an arachnoid cyst of the optic nerve sheath.25 Another case series described improvement in visual function after ONSF in a patient with traumatic optic neuropathy and radiographic evidence of an optic nerve sheath hematoma.26 This same case series showed improvement in visual function in three patients with traumatic optic neuropathy who underwent ONSF combined with optic canal decompression.26

Based on retrospective case series and case reports, there was enthusiasm for ONSF as an effective treatment for nonarteritic anterior ischemic optic neuropathy (NAION), the most common cause of an acute optic neuropathy in patients older than 55 years of age.27 The National Eye Institute (NEI) funded a prospective multicentered study to assess the efficacy of ONSF in acute NAION. The Ischemic Optic Neuropathy Decompression Trial (IONDT) was a randomized, placebo-controlled trial that found ONSF was not more effective than observation in the final visual outcome of patients with NAION. In addition those patients who underwent ONSF had a greater risk of losing vision compared with the observation group.28,29

Optic Nerve Sheath Fenestration for Elevated Intracranial Pressure
Papilledema can lead to visual loss from optic nerve or retinal (macular) disease (see Figure 4). ONSF is indicated in some cases of papilledema, most commonly for visual loss due to IIH.

IIH is typically encountered in obese women in their second, third, and fourth decades of life; and is characterized by normal neuroimaging and elevated CSF pressure with normal CSF studies (see Table 2). In most cases, IIH can be effectively treated medically with the use of an ICP lowering agent such as acetazolamide and a weight-reduction program.30 Surgical treatment of IIH is achieved through ONSF, a CSF diversion procedure (i.e.lumboperitoneal or ventriculoperitoneal shunt), or venous sinus stenting and is reserved for those patients who cannot tolerate medical therapy or develop progressive symptoms despite maximal medical treatment.30 ONSF is warranted in patients with IIH who are receiving maximal medical therapy and yet have progressive visual loss or impending visual loss with minimal or tolerable headaches. By contrast, a CSF-diversion procedure is preferred over ONSF for those patients with medially resistant, unremitting and disabling headaches with or without visual loss. Recently, several small case series have demonstrated the efficacy of venous sinus stenting in some cases of IIH; however, this therapeutic modality requires further exploration.31–37

In a meta-analysis based on retrospective data of ONSF performed on 423 eyes in patients with IIH, visual acuity improved in 50 % of eyes and visual field improved in 72 % of eyes.38 In the same meta-analysis, worsening of the visual field or visual acuity occurred in only 11 % of cases. In a recent study, 62 IIH patients with bilateral papilledema who underwent unilateral ONSF were found to have a decrease in the median grade of papilledema in both the operated and the nonoperated eye. The median grade of papilledema in the operated eye decreased from grade 3 preoperatively to grade 0.5 by 12 months. The median grade of papilledema in the nonoperated eye decreased from grade 2 before surgery to a grade 1 12 months postoperatively39 (see Table 3). Studies have shown that ONSF is safe and effective in pediatric patients as well.40,41 A retrospective chart review of 17 pediatric eyes with IIHshowed decreased ONH edema with stabilization or improvement in visual function in all eyes after ONSF.41

ONSF is not an entirely benign procedure and can be associated with both minor and profound ocular complications (see Table 4). In a review of the published IIH literature, the complication rate of ONSF was found to range broadly between 4.8–45 % with a mean of 12.9 %.30 In the same review of 317 cases of ONSF, 13 % of cases were deemed a failure, which was defined as progressive visual loss despite the surgery or need for reoperation.30 In addition, case reports have described patients with progressive visual loss after ONSF due to sustained elevated ICP.42 A recent study using an experimental rat model found optic atrophy and degeneration of RGCs after ONSF, suggesting that in humans RGC neurodegeneration may be a consequence of ONSF.43

Although ONSF is performed most commonly in the setting of papilledema due to IIH, ONSF is also indicated in cases of papilledema with impending or progressive visual loss due to an unresectable CNS mass, an arteriovascular malformation of the vein of Galen, venous sinus thrombosis, and obstruction of the cerebral venous system from a compressive lesion.20 In addition, case reports have described patients with cryptococcal meningitis and visual loss caused by papilledema who have been successfully treated with ONSF.44–46

Surgical Technique
The three main surgical approaches for ONSF are superior eyelid, lateral orbital, and medial transconjunctival.

In the following section we will provide a general overview of each approach with a special emphasis on the medial transconjunctival approach, which is the preferred technique of the authors.

Superior Eyelid Approach
Approaching the superior and lateral orbit via the anterior superior eyelid crease has been a surgical method preferred by orbital surgeons for removal of intraorbital lesions. In recent years, the anterior superior eyelid crease approach has been adopted by neurosurgery because of the excellent surgical exposure it provides to the anterior skull base.47 A particular advantage of this approach is the excellent cosmetic outcome because the incision can be hidden within the natural superior eyelid crease.48 For the purposes of performing an ONSF, the medial intraconal space is accessed through a superomedial eyelid crease incision.49 The orbital septum is opened and the medial horn of the levator aponeurosis pushed laterally. With blunt dissection, a plane is created between the medial rectus muscle and the superior oblique tendon to access the posterior orbit avoiding the superior ophthalmic vein and vortex veins. With further posterior dissection, the optic nerve comes into view and a slit or rectangular window is created within the optic nerve sheath. Advantages of the superiomedial eyelid approach for an ONSF include decreased traction on the globe, decreased operating time, decreased bleeding, limited sharp dissection of normal tissue, and absence of extraocular muscle traction or dissection. Limitations of this approach include an increased distance from incision site to the optic nerve and an external (skin) incision compared with the medial transconjunctival approach (see below).

Lateral Orbital Approach
The approach to the intraconal orbital space for ONSF through the lateral conjunctiva was first described in 1872.1 Subsequently, the lateral approach was modified by a number of surgeons to improve access to the optic nerve. In 1988, Tse and colleagues described a lateral orbitotomy approach for ONSF.50 The procedure begins with an en bloc removal of the lateral orbital wall. The periorbita is incised in a T-shaped fashion and blunt dissection of the perimuscular fasical sheaths is performed until the lateral rectus muscle is identified. A traction suture is placed under the insertion of the lateral rectus muscle and the suture is anchored medially, adducting the eye in order to move the optic nerve laterally. Dissection with specially designed orbital-neurosurgical brain retractors is used to gain access to the optic nerve. Once the retrobulbar portion of the optic nerve is adequately exposed, an operating microscope is used to assist in a window incision of the optic nerve sheath. The periorbita is closed with interrupted sutures and the bone fragment is re-approximated to the lateral orbital wall using nonabsorbable suture. Advantages of the lateral approach to ONSF include exposure of a longer segment of the optic nerve. Limitations of this approach include longer operating time, an external incision, and a more complex surgical procedure that requires removal of the orbital rim.20

Medial Transconjunctival Approach
The medial approach to the retrobulbar optic nerve was first described by Galbraith and Sullivan in 1973.51 The following description is the techniqueperformed at the Duke Eye Center (see Figure 5).41 After induction of general anesthesia, a medial limbal conjunctival peritomy is performed and the conjunctiva incision is extended superiorly and inferiorly. The medial rectus muscle is isolated and the tendon is secured with a double armed 6–0 vicryl suture. The muscle is detached from the globe using scissors, leaving a small remnant of muscle tendon attached to the globe. A 5–0 dacron traction suture is placed through the muscle tendon, and the globe is retracted laterally. The long posterior ciliary arteries are then identified between the superior and inferior poles of the insertion of the medial rectus muscle. With the aid of small malleable retractors the retrobulbar optic nerve is approached through the posterior reflection of tenon’s capsule and retrobulbar orbital fat. The orbital fat is retracted away from the optic nerve with small strips of cottonoids. A small angled forceps is used to improve exposure of the optic nerve. With the assistance of the operating microscope a sharp blade on a long handle is used to incise the optic nerve sheath approximately 2 mm posterior to the globe with careful attention to avoid any blood vessels on the surface of the nerve. A fine toothed forceps is inserted into the incision site and extended posteriorly with microscissors to a total length of 3–5 mm. A tenotomy hook is sometimes inserted into the SAS and moved in the anterior– posterior direction to lyse any arachnoidal trabeculations and adhesions. On completion of the fenestration, the traction suture is removed, and the medial rectus is reattached to the globe using standard strabismus muscle technique. The conjunctiva is closed with 8–0 vicryl sutures. An antibiotic-steroid ointment is applied to the eye and a protective shield is placed over the eye to prevent any direct external pressure. The advantages of the medial transconjunctival approach include increased width of the operating field, minimal distance from incision to the optic nerve, minimal bleeding, and lack of an external incision.

Conclusion
ONSF is a relatively safe and effective surgical procedure in patients with visual loss due to papilledema. Although ONSF has been found to improve visual function in many diseases of the optic nerve, it has been best studied—although without the benefit of level I evidence—in cases of papilledema in the setting of IIH.

Timely ONSF in an IIH patient with visual loss may lead to stabilization and, sometimes, visual function improvement. There are three main approaches to ONSF, each offering its own advantages and limitations.

Article Information:
Disclosure

The authors have no conflicts of interests to declare.

Correspondence

M Tariq Bhatti, MD, Associate Professor, Departments of Ophthalmology and Neurology, Duke University Eye Center, 2351 Erwin Road, DUMC 3802, Durham, NC, 27710-3802, US. E: tariq.bhatti@duke.edu

Support

An unrestricted departmental grant from Research to Prevent Blindness, Inc.

Received

2013-07-05T00:00:00

References

  1. DeWecker L, On incision of the optic nerve in cases of neuroretinitis, Int Ophthalmol Cong Rep, 1872;4:11–14.
  2. H ayreh SS, Optic disc edema in raised intracranial pressure. V. Pathogenesis, Arch Ophthalmol, 1977;95(9):1553–65.
  3. H ayreh SS, Pathogenesis of oedema of the optic disc, Doc Ophthalmol, 1968;24(2):289–411.
  4. H ayreh MS, Hayreh SS, Optic disc edema in raised intracranial pressure. I. Evolution and resolution, Arch Ophthalmol, 1977;95(7):1237–44.
  5. T so MO, Hayreh SS, Optic disc edema in raised intracranial pressure. II. A pathologic study of experimental papilledema, Arch Ophthalmol, 1977;95(8):1448–57.
  6. T so MO, Hayreh SS, Optic disc edema in raised intracranial pressure. IV. Axoplasmic transport in experimental papilledema, Arch Ophthalmol, 1977;95(8):1458–62.
  7. H ayreh SS, Fluids in the anterior part of the optic nerve in health and disease, Surv Ophthalmol, 1978;23(1):1–25.
  8. H ayreh SS, Hayreh MS, Optic disc edema in raised intracranial pressure. II. Early detection with fluorescein fundus angiography and stereoscopic color photography, Arch Ophthalmol, 1977;95(7):1245–54.
  9. M iller NR, Newman NJ, Biousse V, Kerrison JB, Walsh & Hoyt’s Clinical Neuro-Ophthalmology. 6th ed. Vol. 1; Lippincott Williams & Wilkins, 2004;3752.
  10. O’Neill EC, Danesh-Meyer HV, Connell PP, et al., The optic nerve head in acquired optic neuropathies, Nat Rev Neurol, 2010;6(4):221–36.
  11. Schirmer CM, Hedges TR, 3rd, Mechanisms of visual loss in papilledema, Neurosurg Focus, 2007;23(5):E5.
  12. Killer HE, Jaggi GP, Flammer J, et al., Cerebrospinal fluid dynamics between the intracranial and the subarachnoid space of the optic nerve. Is it always bidirectional?, Brain, 2007;130 (Pt 2):514–20.
  13. Killer HE, Jaggi GP, Miller NR, et al., Cerebrospinal fluid dynamics between the basal cisterns and the subarachnoid space of the optic nerve in patients with papilloedema, Br J Ophthalmol, 2011;95(6):822–7.
  14. Yazici Z, Yazici B, Tuncel E, Findings of magnetic resonance imaging after optic nerve sheath decompression in patients with idiopathic intracranial hypertension, Am J Ophthalmol, 2007;144(3):429–35.
  15. H amed LM, Tse DT, Glaser JS, et al., Neuroimaging of the optic nerve after fenestration for management of pseudotumor cerebri, Arch Ophthalmol, 1992;110(5):636–9.
  16. Seiff SR, Shah A, model for the mechanism of optic nerve sheath fenestration, Arch Ophthalmol, 1990;108(9):1326–9.
  17. T sai JC, Petrovich MS, Sadun AA, Histopathological and ultrastructural examination of optic nerve sheath decompression, Br J Ophthalmol, 1995;79(2):182–5.
  18. Davidson SI, A surgical approach to plerocephalic disc oedema, Trans Ophthalmol Soc U K, 1970;89:669–90.
  19. M ohamed IG, Roa W, Fulton D, et al., Optic nerve sheath fenestration for a reversible optic neuropathy in radiation oncology, Am J Clin Oncol, 2000;23(4):401–5.
  20. Sergott RC, Optic nerve sheath decompression: history, techniques, and indications, Int Ophthalmol Clin, 1991;31(4):71–81. 21. Beck RW, Greenberg HS, Post-decompression optic neuropathy, J Neurosurg, 1985;63(2):196–9.
  21. A llen RC, Nerad JA, Kattah JC, Lee AG, Resolution of optic nerve edema and improved visual function after optic nerve sheath fenestration in a patient with osteopetrosis, Am J Ophthalmol, 2006;141(5):945–7.
  22. V anderveen DK, Nihalani BR, Barron P, Anderson RL, Optic nerve sheath fenestration for an isolated optic nerve glioma, J AAPOS, 2009;13(1):88–90.
  23. T homas S, Tan J, Lawden M, Sampath R, Optic nerve sheath fenestration for intracranial hypertension associated with chronic inflammatory demyelinating polyneuropathy, Ophthal Plast Reconstr Surg, 2004;20(4):325–7.
  24. Guy J, Sherwood M, Day AL, Surgical treatment of progressive visual loss in traumatic optic neuropathy. Report of two cases, J Neurosurg, 1989;70(5):799–801.
  25. M auriello JA, DeLuca J, Krieger A, et al., Management of traumatic optic neuropathy—a study of 23 patients, Br J Ophthalmol, 1992;76(6):349–52.
  26. Sergott RC, Cohen MS, Bosley TM, Savino PJ, Optic nerve decompression may improve the progressive form of nonarteritic ischemic optic neuropathy, Arch Ophthalmol, 1989;107(12):1743–54.
  27. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group, JAMA, 1995. 273(8):625–32.
  28. Dickersin K, Manheimer E, Li T, Surgery for nonarteritic anterior ischemic optic neuropathy, Cochrane Database Syst Rev, 2012;1:CD001538.
  29. Friedman DI, Jacobson DM, Idiopathic intracranial hypertension, J Neuroophthalmol, 2004;24(2):138–45.
  30. A hmed RM, Wilkinson M, Parker GD, et al., Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions, AJNR Am J Neuroradiol, 2011;32(8):1408–14.
  31. Bussière M, Falero R, Nicolle D, et al., Unilateral transverse sinus stenting of patients with idiopathic intracranial hypertension, AJNR Am J Neuroradiol, 2010;31(4):645–50.
  32. Ducruet AF, Crowley RW, McDougall CG, Albuquerque FC, Longterm patency of venous sinus stents for idiopathic intracranial hypertension, J Neurointerv Surg, 2013 [Epub ahead of print].
  33. Dykhuizen MJ, Hall J, Cerebral venous sinus system and stenting in pseudotumor cerebri, Curr Opin Ophthalmol, 2011;22(6):458–62.
  34. Fields JD, Javedani PP, Falardeau J, et al., Dural venous sinus angioplasty and stenting for the treatment of idiopathic intracranial hypertension, J Neurointerv Surg, 2013;5(1):62–8.
  35. H iggins JN, Cousins C, Owler BK, et al., Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting, J Neurol Neurosurg Psychiatry, 2003;74(12):1662–6.
  36. P uffer RC, Mustafa W, Lanzino G, Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature, J Neurointerv Surg, 2013;5(5):483–6.
  37. Feldon SE, Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension, Neurosurg Focus, 2007;23(5):E6.
  38. A lsuhaibani AH, Carter KD, Nerad JA, Lee AG, Effect of optic nerve sheath fenestration on papilledema of the operated and the contralateral nonoperated eyes in idiopathic intracranial hypertension, Ophthalmology, 2011;118(2):412–14.
  39. L ee AG, Patrinely JR, Edmond JC, Optic nerve sheath decompression in pediatric pseudotumor cerebri, Ophthalmic Surg Lasers, 1998;29(6):514–17.
  40. T huente DD, Buckley EG, Pediatric optic nerve sheath decompression, Ophthalmology, 2005;112(4):724–7.
  41. W ilkes BN, Siatkowski RM, Progressive optic neuropathy in idiopathic intracranial hypertension after optic nerve sheath fenestration, J Neuroophthalmol, 2009;29(4):281–3.
  42. Gellrich NC, Stuehmer C, Bormann KH, et al., Degeneration of retinal ganglion cells after optic nerve sheath fenestration in an experimental rat model, J Neuroophthalmol, 2009;29(4):275–80.
  43. Garrity JA, Herman DC, Imes R, et al., Optic nerve sheath decompression for visual loss in patients with acquired immunodeficiency syndrome and cryptococcal meningitis with papilledema, Am J Ophthalmol, 1993;116(4):472–8.
  44. M ilman T, Mirani N, Turbin RE, Optic nerve sheath fenestration in cryptococcal meningitis, Clin Ophthalmol, 2008;2(3):637–9.
  45. C remer PD, Johnston IH, Halmagyi GM, Pseudotumour cerebri syndrome due to cryptococcal meningitis, J Neurol Neurosurg Psychiatry, 1997;62(1):96–8.
  46. A ndaluz N, Romano A, Reddy LV , Zuccarello M, Eyelid approach to the anterior cranial base, J Neurosurg, 2008;109(2):341–6.
  47. P elton RW, The anterior eyelid crease approach to the orbit, Curr Opin Ophthalmol, 2009;20(5):401–5.
  48. P elton RW, Patel BC, Superomedial lid crease approach to the medial intraconal space: a new technique for access to the optic nerve and central space, Ophthal Plast Reconstr Surg, 2001;17(4):241–53.
  49. T se DT, Nerad JA, Anderson RL, Corbett JJ, Optic nerve sheath fenestration in pseudotumor cerebri. A lateral orbitotomy approach, Arch Ophthalmol, 1988;106(10):1458–62.
  50. Galbraith JE, Sullivan JH, Decompression of the perioptic meninges for relief of papilledema, Am J Ophthalmol, 1973;76(5):687–92.

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72